Market cap
$376 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
9.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.1
-
Face value
--
-
Shares outstanding
46,671,500
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
| 373.5 | 0.8 | 192.7 | 103.8 | 4.3 | -- | -- |
|
BSE Sensex*
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
|---|---|---|
|
Vigil Neuroscience (VIGL)
| -49.4 | -73.0 |
|
S&P Small-Cap 600
| 7.0 | 13.9 |
|
BSE Sensex
| 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
8.1 | 375.7 | 0.5 | -92.2 | -21,199.8 | -163.3 | -- | 9.1 |
| 0.1 | 3.4 | 0.0 | -27.5 | -- | -- | -- | 2.6 |
Shareholding Pattern
View DetailsAbout Vigil Neuroscience (VIGL)
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States.... The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. It also developing VG-3927, an orally available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts. As of August 5, 2025, Vigil Neuroscience, Inc. operates as a subsidiary of Sanofi. Read more
-
President, CEO & Director
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
-
President, CEO & Director
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
-
Headquarters
Watertown, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Vigil Neuroscience (VIGL)
What is the current share price of Vigil Neuroscience Inc (VIGL) Today?
The share price of Vigil Neuroscience Inc (VIGL) is $8.05 (NASDAQ) as of 05-Aug-2025 09:30 EDT. Vigil Neuroscience Inc (VIGL) has given a return of 4.27% in the last 3 years.
What is the current PB & PE ratio of Vigil Neuroscience Inc (VIGL)?
Since, TTM earnings of Vigil Neuroscience Inc (VIGL) is negative, P/E ratio is not available.
The P/B ratio of Vigil Neuroscience Inc (VIGL) is 9.11 times as on 05-Aug-2025, a 124 premium to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.84
|
0.99
|
|
2023
|
-1.59
|
1.13
|
|
2022
|
-7.10
|
2.54
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
What is the 52 Week High and Low of Vigil Neuroscience Inc (VIGL)?
The 52-week high and low of Vigil Neuroscience Inc (VIGL) are Rs 8.10 and Rs 1.31 as of 13-Jun-2026.
What is the market cap of Vigil Neuroscience Inc (VIGL)?
Vigil Neuroscience Inc (VIGL) has a market capitalisation of $ 376 Mln as on 05-Aug-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Vigil Neuroscience Inc (VIGL)?
Before investing in Vigil Neuroscience Inc (VIGL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.